Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-05-05

Clinical Trial Update: A Study to Evaluate the Effects of Aflibercept on QTc Interval in Cancer Patients [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the effects of aflibercept on QTc interval in cancer patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Zaltrap (ramucirumab)

Snippet

Sponsor: Sanofi | Conditions: Cancer | Phase 1 | Status: COMPLETED